Policy Risks Related to Sales to China and Concentrated Purchasing
First written in FY2023. 4 of 5 entries say "Worsened", first in FY2024. Latest entry: FY2026.
Asahi Intecc moved to the "Worse" side of this theme in 2024, 5 years after the typical company in this theme (2019).
The whole theme swung hardest in 2017: 3 of 10 companies on the "Worse" side.
5 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Of our group's consolidated sales for the fiscal year, medical business sales in China totaled ¥37.417 billion, accounting for 25.7% of total consolidated sales.」
China medical sales rose from ¥28.283 billion to ¥37.417 billion, while the ratio of consolidated sales rose from 23.6% to 25.7%, increasing our concentration in the Chinese market. - 2026-08-14WorsenedRevision of earnings forecasts
「China 28,283 539 28,823 China 37,417 564 37,982」
In the regional revenue table, Medical Business revenue in China increased from ¥28,283 million to ¥37,417 million, while consolidated revenue increased from ¥28,823 million to ¥37,982 million. Revenue concentration in the Chinese market increased further. - FY2025WorsenedAnnual report
「Of the Group's consolidated net sales for the current consolidated fiscal year, China sales in the Medical Business amounted to ¥28.283 billion, accounting for 23.6% of total consolidated net sales. We recognize the Chinese market as an important market with high growth potential over the medium to long term, but uncertainty has increased due to the intensifying trade tensions between the United States and China, the Chinese government and authorities' policies favoring domestic products, and the promotion of centralized procurement.」
China sales in the Medical Business rose from ¥24.033 billion to ¥28.283 billion, while the ratio to consolidated net sales rose from 22.3% to 23.6%, increasing the Group's concentration in the Chinese market. - FY2024WorsenedAnnual report
「Of the Group's consolidated net sales for the current consolidated fiscal year, China sales in the Medical Business amounted to ¥24.033 billion, accounting for 22.3% of total consolidated net sales. We recognize the Chinese market as an important market with high growth potential over the medium to long term, but uncertainty has increased due to the intensifying trade tensions between the United States and China, the Chinese government and authorities' policies favoring domestic products, and the promotion of centralized procurement.」
China sales in the Medical Business amounted to ¥24.033 billion, and the ratio to consolidated net sales rose from 18.8% in the previous fiscal year to 22.3%, increasing the Group's concentration in the Chinese market. - FY2023First statedAnnual report
「Of the group’s consolidated sales for the current consolidated fiscal year, Medical segment sales in China were ¥1,697.4 million, accounting for 18.8% of total consolidated sales. The company recognises the Chinese market as an important market with high medium- to long-term growth potential, but uncertainty is increasing due to escalating US-China trade tensions, preferential policies for domestic products by the Chinese government and authorities, and the promotion of centralised procurement.」
The company newly disclosed the concentration of Medical segment sales in China at ¥1,697.4 million, or 18.8% of consolidated sales, and disclosed uncertainty arising from US-China trade tensions, preferential policies for domestic products and centralised procurement as separate risks.